Mesenchymal Stem Cell Immune Modulation for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for canine atopic dermatitis lack reliable biomarkers, and existing treatments are ineffective in addressing the immune imbalance underlying the condition.
Innovation Solution
The use of mesenchymal stem cells (MSCs), modified or stimulated to produce cytokines, is administered to patients, along with diagnostic methods involving markers such as miR-203, miR-483, PIAS1, RORA, SH2B1, and PDE4D to identify and treat atopic dermatitis by modulating the immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are administered to treat atopic dermatitis, then immune balance is restored and symptoms are reduced, but the complexity of the treatment protocol increases due to the need for diagnostic biomarker testing and cell modification
Solution Approach 1:
The patent applies preliminary action by conducting diagnostic testing for biomarkers (miR-203, miR-483, PIAS1, RORA, SH2B1, PDE4D) before administering mesenchymal stem cells. This pre-screening identifies suitable candidates and determines the appropriate cell modification strategy, ensuring treatment effectiveness while optimizing the overall protocol complexity through targeted rather than universal application.
Solution Approach 2:
The patent utilizes parameter changes by modifying mesenchymal stem cells through genetic engineering or stimulation to alter their cytokine production profiles. These parameter modifications enable the cells to specifically target and modulate the immune imbalance characteristic of atopic dermatitis, improving treatment effectiveness while allowing for standardized treatment protocols.
2Measurement precision
If diagnostic biomarkers are used to identify atopic dermatitis patients, then diagnostic accuracy improves, but the cost and complexity of diagnostic testing increases
Solution Approach 1:
The patent applies universality by selecting biomarkers that serve multiple functions: miR-203 and miR-483 provide diagnostic accuracy for atopic dermatitis identification, while also serving as potential therapeutic targets and predictors of treatment response. This multi-functionality justifies the diagnostic testing complexity by yielding multiple clinical benefits from a single testing approach.
Solution Approach 2:
The patent uses biomarkers as intermediaries between the complex immune dysregulation of atopic dermatitis and the therapeutic intervention. These biomarkers (miR-203, miR-483, PIAS1, RORA, SH2B1, PDE4D) act as measurable proxies that bridge the gap between disease pathophysiology and diagnostic/testing capabilities, enabling precise patient selection without requiring direct measurement of immune function.
3Reliability
If mesenchymal stem cells are modified or stimulated to produce cytokines, then treatment efficacy increases, but the manufacturing and administration complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying mesenchymal stem cells through controlled genetic engineering or stimulation protocols to alter their cytokine production. These parameter modifications (gene insertion, promoter activation, cytokine stimulation) are performed in standardized laboratory conditions, improving treatment efficacy while enabling reproducible manufacturing that offsets the increased complexity through protocol standardization.
Solution Approach 2:
The patent utilizes self-service by designing mesenchymal stem cell therapies that autonomously modulate the patient's immune system upon administration. The modified cells self-regulate their cytokine production in response to the disease state, eliminating the need for complex external delivery systems or continuous monitoring, thereby simplifying administration despite the initial manufacturing complexity.
Data Source
AI summary
Provided are methods of diagnosis and treatment of atopic dermatitis.